Commentary
2021-02-19
市傳微博來港上市 留意港交所25416購
港股上日(18日)北水恢復惟未能帶動大市延續牛年升勢,大市跌近500點下「三萬一」關口得而復失。看好可留意恆指牛證61463,收回價30173點,實際槓桿78.45倍,換股比率10000:1。相反看淡亦可留意新上市恆指熊證63957,收回價31050點,換股比率10000:1。
 
有消息指在美上市的新浪微博(WB.US)有意來港作第二上市,港交所(0388)有望受惠向好。集團股價上日逆市微升0.4%並曾再度破頂,惟輪證資金有逾4690萬元從其好倉流出。投資者看好可留意購證25416,行使價668.88元,實際槓桿5.57倍,21年7月到期。相反看淡亦可留意沽證28731,行使價488.88元,實際槓桿5.37倍,21年7月到期。
 
獲「女股神」旗下基金青睞的眾安在線(6060),平安好醫生(1833)及移卡(9923)上日全線回吐,下跌3%至11%不等。投資者如有意趁低吸納,可留意以下輪證部署。
 
平醫購證14567,行使價155.88元,實際槓桿2.62倍,21年9月到期。
新上市平醫牛證63971,收回價125元,換股比率100:1。
新上市眾安購證15039,行使價84.68元,21年8月到期。
移卡購證25419,行使價108.88元,實際槓桿2.19倍,21年7月到期。
The information on this material is provided and published by Haitong International Securities Company Limited (“HTI”), a corporation holding licences for Type 1 (dealing in securities) and Type 4 (advising in securities) regulated activities pursuant to the Securities and Futures Ordinance (Cap. 571). The contents of this material has not been reviewed or approved by the Securities and Futures Commission. Any and all information provided on this material is for reference only and does not constitute an offer, a solicitation of an offer or any advice or recommendation to buy or sell any financial products. The prices of structured products such as Warrants and/or CBBCs may fluctuate greatly and past performance is not indicative of future performance. The value of structured products may become zero on or before the expiry date and investors may sustain a total loss of investment. CBBCs have a mandatory call feature and are subject to early termination, upon which (i) investors in category N CBBCs will lose all their investments in CBBCs; and (ii) the residual value of category R CCBCs may be zero. Structured products issued by HTI or its affiliate are uncollateralised and investors are relying on the issuer’s credit worthiness in determining the issuer’s ability to meet its obligations under the structured products. If the Issuer is insolvent or defaults in payment, investors may not recover part or all of the amount due. An investor should read carefully the relevant listing documents (and any documents appendix thereto) and the relevant supplemental listing document to understand the full details of the warrant and/or CBBC (including risk factors), and due consideration have been given having considered the nature and risks involved in investing in these products, to decide whether the investment is suitable for an investor’s individual circumstances and, if necessary, an investor should consult their professional advisers. HTI is also the liquidity provider for the warrants and/or CBBCs (“Structured Products”) referred to in the material . HTI may be the only person quoting prices (or market making) for the Structured Products on the exchange. As such, the secondary market for the Structured Products may be limited. HTI (together with its subsidiaries and affiliates, “HTI Group”) provides the information in good faith and has used its best endeavours to ensure that the information provided is accurate and complete. HTI Group however does not represent or warrant the completeness or accuracy of the information and HTI Group. Haitong International Securities Company Limited may make a market in the securities and/ or the derivatives on these securities herein covered. Haitong International Securities Company Limited and/or its group company(ies) may have presently, or have had within the last 12 months, an investment banking relationship with the underlying entity of the securities herein covered. Haitong International Securities Company Limited is a member of Haitong International Securities Group which in turn belongs to group of companies of Haitong Securities Co., Ltd. HTISG and our affiliates, officers, directors, and employees, excluding the analysts responsible for the content of this document, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives, if any, referred to in this document. Haitong International Securities Company Limited and/or its group company(ies) and its affiliates, officers, directors, and employees, excluding the analysts responsible for the content of this document, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives, if any, referred to in this document.